O	0	8	Adjuvant
B-intervention	9	18	denosumab
O	19	21	in
O	22	28	breast
O	29	35	cancer
O	36	37	(
O	37	42	ABCSG
O	42	43	-
O	43	45	18
O	45	46	)
O	46	47	:
O	48	49	a
O	50	61	multicentre
O	61	62	,
O	63	73	randomised
O	73	74	,
O	75	81	double
O	81	82	-
O	82	87	blind
O	87	88	,
O	89	96	placebo
O	96	97	-
O	97	107	controlled
O	108	113	trial
O	113	114	.

O	115	123	Adjuvant
O	124	133	endocrine
O	134	141	therapy
O	142	153	compromises
O	154	158	bone
O	159	165	health
O	166	168	in
O	169	177	patients
O	178	182	with
O	183	189	breast
O	190	196	cancer
O	196	197	,
O	198	205	causing
O	206	216	osteopenia
O	216	217	,
O	218	230	osteoporosis
O	230	231	,
O	232	235	and
O	236	245	fractures
O	245	246	.

O	247	261	Antiresorptive
O	262	272	treatments
O	273	277	such
O	278	280	as
O	281	296	bisphosphonates
O	297	304	prevent
O	305	308	and
O	309	319	counteract
O	320	325	these
O	326	330	side
O	330	331	-
O	331	338	effects
O	338	339	.

O	340	342	In
O	343	347	this
O	348	353	trial
O	353	354	,
O	355	357	we
O	358	363	aimed
O	364	366	to
O	367	378	investigate
O	379	382	the
O	383	390	effects
O	391	393	of
O	394	397	the
O	398	402	anti
O	402	403	-
O	403	407	RANK
O	408	414	ligand
O	415	423	antibody
O	424	433	denosumab
O	434	436	in
O	437	451	postmenopausal
O	451	452	,
O	453	462	aromatase
O	463	472	inhibitor
O	472	473	-
O	473	480	treated
O	481	489	patients
O	490	494	with
O	495	500	early
O	500	501	-
O	501	506	stage
O	507	514	hormone
O	515	523	receptor
O	523	524	-
O	524	532	positive
O	533	539	breast
O	540	546	cancer
O	546	547	.

O	548	550	In
O	551	555	this
O	556	567	prospective
O	567	568	,
O	569	575	double
O	575	576	-
O	576	581	blind
O	581	582	,
O	583	590	placebo
O	590	591	-
O	591	601	controlled
O	601	602	,
O	603	608	phase
O	609	610	3
O	611	616	trial
O	616	617	,
B-eligibility	618	632	postmenopausal
I-eligibility	633	641	patients
I-eligibility	642	646	with
I-eligibility	647	652	early
I-eligibility	653	660	hormone
I-eligibility	661	669	receptor
I-eligibility	669	670	-
I-eligibility	670	678	positive
I-eligibility	679	685	breast
I-eligibility	686	692	cancer
I-eligibility	693	702	receiving
I-eligibility	703	712	treatment
I-eligibility	713	717	with
I-eligibility	718	727	aromatase
I-eligibility	728	738	inhibitors
O	739	743	were
O	744	752	randomly
O	753	761	assigned
O	762	764	in
O	765	766	a
O	767	768	1
O	768	769	:
O	769	770	1
O	771	776	ratio
O	777	779	to
O	780	787	receive
O	788	794	either
O	795	804	denosumab
O	805	807	60
O	808	810	mg
O	811	813	or
O	814	821	placebo
O	822	834	administered
O	835	849	subcutaneously
O	850	855	every
O	856	857	6
O	858	864	months
O	865	867	in
O	868	870	58
O	871	876	trial
O	877	884	centres
O	885	887	in
B-location	888	895	Austria
O	896	899	and
B-location	900	906	Sweden
O	906	907	.

O	908	916	Patients
O	917	921	were
O	922	930	assigned
O	931	933	by
O	934	936	an
O	937	948	interactive
O	949	954	voice
O	955	963	response
O	964	970	system
O	970	971	.

O	972	975	The
O	976	989	randomisation
O	990	998	schedule
O	999	1003	used
O	1004	1005	a
O	1006	1014	randomly
O	1015	1023	permuted
O	1024	1029	block
O	1030	1036	design
O	1037	1041	with
O	1042	1047	block
O	1048	1053	sizes
O	1054	1055	2
O	1056	1059	and
O	1060	1061	4
O	1061	1062	,
O	1063	1073	stratified
O	1074	1076	by
O	1077	1081	type
O	1082	1084	of
O	1085	1093	hospital
O	1094	1103	regarding
O	1104	1111	Hologic
O	1112	1118	device
O	1119	1122	for
O	1123	1126	DXA
O	1127	1132	scans
O	1132	1133	,
O	1134	1142	previous
O	1143	1152	aromatase
O	1153	1162	inhibitor
O	1163	1166	use
O	1166	1167	,
O	1168	1171	and
O	1172	1180	baseline
O	1181	1185	bone
O	1186	1193	mineral
O	1194	1201	density
O	1201	1202	.

O	1203	1211	Patients
O	1211	1212	,
O	1213	1221	treating
O	1222	1232	physicians
O	1232	1233	,
O	1234	1247	investigators
O	1247	1248	,
O	1249	1253	data
O	1254	1262	managers
O	1262	1263	,
O	1264	1267	and
O	1268	1271	all
O	1272	1277	study
O	1278	1287	personnel
O	1288	1292	were
O	1293	1299	masked
O	1300	1302	to
O	1303	1312	treatment
O	1313	1323	allocation
O	1323	1324	.

O	1325	1328	The
O	1329	1336	primary
O	1337	1345	endpoint
O	1346	1349	was
B-outcome-Measure	1350	1354	time
I-outcome-Measure	1355	1359	from
I-outcome-Measure	1360	1373	randomisation
I-outcome-Measure	1374	1376	to
I-outcome-Measure	1377	1382	first
I-outcome-Measure	1383	1391	clinical
I-outcome-Measure	1392	1400	fracture
O	1400	1401	,
O	1402	1410	analysed
O	1411	1413	by
O	1414	1423	intention
O	1424	1426	to
O	1427	1432	treat
O	1432	1433	.

O	1434	1436	As
O	1437	1439	an
O	1440	1450	additional
O	1451	1462	sensitivity
O	1463	1471	analysis
O	1471	1472	,
O	1473	1475	we
O	1476	1480	also
O	1481	1489	analysed
O	1490	1493	the
O	1494	1501	primary
O	1502	1510	endpoint
O	1511	1513	on
O	1514	1517	the
O	1518	1521	per
O	1521	1522	-
O	1522	1530	protocol
O	1531	1541	population
O	1541	1542	.

O	1543	1551	Patients
O	1552	1556	were
O	1557	1564	treated
O	1565	1570	until
O	1571	1574	the
O	1575	1587	prespecified
O	1588	1594	number
O	1595	1597	of
O	1598	1601	247
O	1602	1607	first
O	1608	1616	clinical
O	1617	1626	fractures
O	1627	1630	was
O	1631	1638	reached
O	1638	1639	.

O	1640	1644	This
O	1645	1650	trial
O	1651	1653	is
O	1654	1661	ongoing
O	1662	1663	(
O	1663	1671	patients
O	1672	1675	are
O	1676	1678	in
O	1679	1685	follow
O	1685	1686	-
O	1686	1688	up
O	1688	1689	)
O	1690	1693	and
O	1694	1696	is
O	1697	1707	registered
O	1708	1712	with
O	1713	1716	the
O	1717	1725	European
O	1726	1734	Clinical
O	1735	1741	Trials
O	1742	1750	Database
O	1750	1751	,
O	1752	1758	number
O	1759	1763	2005
O	1763	1764	-
O	1764	1770	005275
O	1770	1771	-
O	1771	1773	15
O	1773	1774	,
O	1775	1778	and
O	1779	1783	with
O	1784	1798	ClinicalTrials
O	1798	1799	.
O	1799	1802	gov
O	1802	1803	,
O	1804	1810	number
O	1811	1822	NCT00556374
O	1822	1823	.

O	1824	1831	Between
O	1832	1835	Dec
O	1836	1838	18
O	1838	1839	,
O	1840	1844	2006
O	1844	1845	,
O	1846	1849	and
O	1850	1854	July
O	1855	1857	22
O	1857	1858	,
O	1859	1863	2013
O	1863	1864	,
B-total-participants	1865	1869	3425
O	1870	1878	eligible
O	1879	1887	patients
O	1888	1892	were
O	1893	1901	enrolled
O	1902	1906	into
O	1907	1910	the
O	1911	1916	trial
O	1916	1917	,
O	1918	1920	of
O	1921	1925	whom
B-total-participants	1926	1930	3420
O	1931	1935	were
O	1936	1944	randomly
O	1945	1953	assigned
O	1954	1956	to
O	1957	1964	receive
O	1965	1974	denosumab
O	1975	1977	60
O	1978	1980	mg
O	1981	1982	(
O	1982	1983	n
O	1983	1984	=
B-intervention-participants	1984	1988	1711
O	1988	1989	)
O	1990	1992	or
B-control	1993	2000	placebo
O	2001	2002	(
O	2002	2003	n
O	2003	2004	=
B-control-participants	2004	2008	1709
O	2008	2009	)
O	2010	2024	subcutaneously
O	2025	2030	every
O	2031	2032	6
O	2033	2039	months
O	2039	2040	.

O	2041	2049	Compared
O	2050	2054	with
O	2055	2058	the
O	2059	2066	placebo
O	2067	2072	group
O	2072	2073	,
O	2074	2082	patients
O	2083	2085	in
O	2086	2089	the
O	2090	2099	denosumab
O	2100	2105	group
O	2106	2109	had
O	2110	2111	a
O	2112	2125	significantly
O	2126	2133	delayed
B-outcome	2134	2138	time
I-outcome	2139	2141	to
I-outcome	2142	2147	first
I-outcome	2148	2156	clinical
I-outcome	2157	2165	fracture
O	2166	2167	(
O	2167	2173	hazard
O	2174	2179	ratio
O	2180	2181	[
O	2181	2183	HR
O	2183	2184	]
O	2185	2186	0
O	2186	2187	·
O	2187	2189	50
O	2190	2191	[
O	2191	2193	95
O	2193	2194	%
O	2195	2197	CI
O	2198	2199	0
O	2199	2200	·
O	2200	2202	39
O	2202	2203	-
O	2203	2204	0
O	2204	2205	·
O	2205	2207	65
O	2207	2208	]
O	2208	2209	,
O	2210	2211	p
O	2211	2212	<
O	2212	2213	0
O	2213	2214	·
O	2214	2218	0001
O	2218	2219	)
O	2219	2220	.

O	2221	2224	The
O	2225	2232	overall
O	2233	2238	lower
B-outcome	2239	2245	number
I-outcome	2246	2248	of
I-outcome	2249	2258	fractures
O	2259	2261	in
O	2262	2265	the
O	2266	2275	denosumab
O	2276	2281	group
O	2282	2283	(
B-iv-bin-abs	2283	2285	92
O	2285	2286	)
O	2287	2291	than
O	2292	2294	in
O	2295	2298	the
O	2299	2306	placebo
O	2307	2312	group
O	2313	2314	(
B-cv-bin-abs	2314	2317	176
O	2317	2318	)
O	2319	2322	was
O	2323	2330	similar
O	2331	2333	in
O	2334	2337	all
O	2338	2345	patient
O	2346	2355	subgroups
O	2355	2356	,
O	2357	2366	including
O	2367	2369	in
O	2370	2378	patients
O	2379	2383	with
O	2384	2385	a
O	2386	2390	bone
O	2391	2398	mineral
O	2399	2406	density
O	2407	2408	T
O	2408	2409	-
O	2409	2414	score
O	2415	2417	of
O	2418	2419	-
O	2419	2420	1
O	2421	2423	or
O	2424	2430	higher
O	2431	2433	at
O	2434	2442	baseline
O	2443	2444	(
O	2444	2445	n
O	2445	2446	=
O	2446	2450	1872
O	2450	2451	,
O	2452	2454	HR
O	2455	2456	0
O	2456	2457	·
O	2457	2459	44
O	2460	2461	[
O	2461	2463	95
O	2463	2464	%
O	2465	2467	CI
O	2468	2469	0
O	2469	2470	·
O	2470	2472	31
O	2472	2473	-
O	2473	2474	0
O	2474	2475	·
O	2475	2477	64
O	2477	2478	]
O	2478	2479	,
O	2480	2481	p
O	2481	2482	<
O	2482	2483	0
O	2483	2484	·
O	2484	2488	0001
O	2488	2489	)
O	2490	2493	and
O	2494	2496	in
O	2497	2502	those
O	2503	2507	with
O	2508	2509	a
O	2510	2514	bone
O	2515	2522	mineral
O	2523	2530	density
O	2531	2532	T
O	2532	2533	-
O	2533	2538	score
O	2539	2541	of
O	2542	2546	less
O	2547	2551	than
O	2552	2553	-
O	2553	2554	1
O	2555	2562	already
O	2563	2565	at
O	2566	2574	baseline
O	2575	2576	(
O	2576	2577	n
O	2577	2578	=
O	2578	2582	1548
O	2582	2583	,
O	2584	2586	HR
O	2587	2588	0
O	2588	2589	·
O	2589	2591	57
O	2592	2593	[
O	2593	2595	95
O	2595	2596	%
O	2597	2599	CI
O	2600	2601	0
O	2601	2602	·
O	2602	2604	40
O	2604	2605	-
O	2605	2606	0
O	2606	2607	·
O	2607	2609	82
O	2609	2610	]
O	2610	2611	,
O	2612	2613	p
O	2613	2614	=
O	2614	2615	0
O	2615	2616	·
O	2616	2619	002
O	2619	2620	)
O	2620	2621	.

O	2622	2625	The
O	2626	2633	patient
B-outcome	2634	2643	incidence
I-outcome	2644	2646	of
I-outcome	2647	2654	adverse
I-outcome	2655	2661	events
O	2662	2664	in
O	2665	2668	the
O	2669	2675	safety
O	2676	2684	analysis
O	2685	2688	set
O	2689	2690	(
O	2690	2693	all
O	2694	2702	patients
O	2703	2706	who
O	2707	2715	received
O	2716	2718	at
O	2719	2724	least
O	2725	2728	one
O	2729	2733	dose
O	2734	2736	of
O	2737	2742	study
O	2743	2747	drug
O	2747	2748	)
O	2749	2752	did
O	2753	2756	not
O	2757	2763	differ
O	2764	2771	between
O	2772	2775	the
O	2776	2785	denosumab
O	2786	2791	group
O	2792	2793	(
B-iv-bin-abs	2793	2797	1366
O	2798	2804	events
O	2804	2805	,
B-iv-bin-percent	2806	2808	80
I-iv-bin-percent	2808	2809	%
O	2809	2810	)
O	2811	2814	and
O	2815	2818	the
O	2819	2826	placebo
O	2827	2832	group
O	2833	2834	(
B-cv-bin-abs	2834	2838	1334
O	2839	2845	events
O	2845	2846	,
B-cv-bin-percent	2847	2849	79
I-cv-bin-percent	2849	2850	%
O	2850	2851	)
O	2851	2852	,
O	2853	2856	nor
O	2857	2860	did
O	2861	2864	the
B-outcome	2865	2872	numbers
I-outcome	2873	2875	of
I-outcome	2876	2883	serious
I-outcome	2884	2891	adverse
I-outcome	2892	2898	events
O	2899	2900	(
B-iv-bin-abs	2900	2903	521
O	2904	2906	vs
B-cv-bin-abs	2907	2910	511
O	2911	2912	[
B-iv-bin-percent	2912	2914	30
I-iv-bin-percent	2914	2915	%
O	2916	2918	in
O	2919	2923	each
O	2924	2929	group
O	2929	2930	]
O	2930	2931	)
O	2931	2932	.

O	2933	2936	The
O	2937	2941	main
O	2942	2949	adverse
O	2950	2956	events
O	2957	2961	were
B-outcome	2962	2972	arthralgia
O	2973	2976	and
O	2977	2982	other
B-outcome	2983	2992	aromatase
I-outcome	2992	2993	-
I-outcome	2993	3002	inhibitor
I-outcome	3003	3010	related
I-outcome	3011	3019	symptoms
O	3019	3020	;
O	3021	3023	no
O	3024	3034	additional
O	3035	3043	toxicity
O	3044	3048	from
O	3049	3052	the
O	3053	3058	study
O	3059	3063	drug
O	3064	3067	was
O	3068	3076	reported
O	3076	3077	.

O	3078	3085	Despite
O	3086	3095	proactive
O	3096	3108	adjudication
O	3109	3111	of
O	3112	3117	every
O	3118	3127	potential
O	3128	3141	osteonecrosis
O	3142	3144	of
O	3145	3148	the
O	3149	3152	jaw
O	3153	3155	by
O	3156	3158	an
O	3159	3172	international
O	3173	3179	expert
O	3180	3185	panel
O	3185	3186	,
O	3187	3189	no
O	3190	3195	cases
O	3196	3198	of
B-outcome	3199	3212	osteonecrosis
I-outcome	3213	3215	of
I-outcome	3216	3219	the
I-outcome	3220	3223	jaw
O	3224	3228	were
O	3229	3237	reported
O	3237	3238	.

O	3239	3241	93
O	3242	3250	patients
O	3251	3252	(
O	3252	3253	3
O	3253	3254	%
O	3255	3257	of
O	3258	3261	the
O	3262	3266	full
O	3267	3275	analysis
O	3276	3279	set
O	3279	3280	)
B-outcome	3281	3285	died
O	3286	3292	during
O	3293	3296	the
O	3297	3302	study
O	3302	3303	,
O	3304	3306	of
O	3307	3312	which
O	3313	3316	one
O	3317	3322	death
O	3323	3324	(
O	3324	3326	in
O	3327	3330	the
O	3331	3340	denosumab
O	3341	3346	group
O	3346	3347	)
O	3348	3351	was
O	3352	3359	thought
O	3360	3362	to
O	3363	3365	be
O	3366	3373	related
O	3374	3376	to
O	3377	3380	the
O	3381	3386	study
O	3387	3391	drug
O	3391	3392	.

O	3393	3401	Adjuvant
O	3402	3411	denosumab
O	3412	3414	60
O	3415	3417	mg
O	3418	3423	twice
O	3424	3427	per
O	3428	3432	year
O	3433	3440	reduces
O	3441	3444	the
O	3445	3449	risk
O	3450	3452	of
O	3453	3461	clinical
O	3462	3471	fractures
O	3472	3474	in
O	3475	3489	postmenopausal
O	3490	3495	women
O	3496	3500	with
O	3501	3507	breast
O	3508	3514	cancer
O	3515	3524	receiving
O	3525	3534	aromatase
O	3535	3545	inhibitors
O	3545	3546	,
O	3547	3550	and
O	3551	3554	can
O	3555	3557	be
O	3558	3570	administered
O	3571	3578	without
O	3579	3584	added
O	3585	3593	toxicity
O	3593	3594	.

O	3595	3600	Since
O	3601	3602	a
O	3603	3607	main
O	3608	3612	side
O	3612	3613	-
O	3613	3619	effect
O	3620	3622	of
O	3623	3631	adjuvant
O	3632	3638	breast
O	3639	3645	cancer
O	3646	3655	treatment
O	3656	3659	can
O	3660	3662	be
O	3663	3676	substantially
O	3677	3684	reduced
O	3685	3687	by
O	3688	3691	the
O	3692	3700	addition
O	3701	3703	of
O	3704	3713	denosumab
O	3713	3714	,
O	3715	3719	this
O	3720	3729	treatment
O	3730	3736	should
O	3737	3739	be
O	3740	3750	considered
O	3751	3754	for
O	3755	3763	clinical
O	3764	3772	practice
O	3772	3773	.

O	3774	3779	Amgen
O	3779	3780	.
